ImmuCell (NASDAQ:ICCC) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

ImmuCell (NASDAQ:ICCC) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.05, FiscalAI reports. The company had revenue of $8.04 million for the quarter, compared to analysts’ expectations of $5.40 million. ImmuCell had a return on equity of 2.69% and a net margin of 2.57%.

ImmuCell Stock Up 0.3%

NASDAQ ICCC traded up $0.03 during mid-day trading on Thursday, reaching $10.22. The stock had a trading volume of 19,294 shares, compared to its average volume of 5,576. The stock has a market cap of $92.82 million, a PE ratio of 127.77 and a beta of 0.61. ImmuCell has a 1 year low of $4.52 and a 1 year high of $12.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.75 and a quick ratio of 2.71. The company has a fifty day moving average price of $10.08 and a 200 day moving average price of $9.01.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered ImmuCell from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, November 4th. One equities research analyst has rated the stock with a Hold rating. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

About ImmuCell

ImmuCell Corporation is a biotechnology and animal health company headquartered in Portland, Maine. The company develops, manufactures, and commercializes products designed to support the health and productivity of livestock, with a primary focus on cattle. ImmuCell’s products include FirstStep Calf Health, an on-farm diagnostic test that helps dairy and beef producers assess whether newborn calves have received adequate passive immunity from colostrum. The company also develops antibody-based products intended to help prevent or manage common diseases affecting young livestock, including neonatal calf diarrhea.